Description
ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA selectively acts at host cell late endosomes rather than targeting toxin or pathogen itself. ABMA has broad-spectrum anti-infection activity.
Product information
CAS Number: 332108-65-3
Molecular Weight: 350.29
Formula: C18H24BrNO
Chemical Name: N-[(5-bromo-2-methoxyphenyl)methyl]adamantan-1-amine
Smiles: COC1=CC=C(Br)C=C1CNC12CC3CC(C1)CC(C2)C3
InChiKey: UCAHJECAHMOSHI-UHFFFAOYSA-N
InChi: InChI=1S/C18H24BrNO/c1-21-17-3-2-16(19)7-15(17)11-20-18-8-12-4-13(9-18)6-14(5-12)10-18/h2-3,7,12-14,20H,4-6,8-11H2,1H3
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : 125 mg/mL (356.85 mM; Need ultrasonic).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
ABMA protects cells against four bacterial toxins (Corynebacterium diphtheriae (DT; EC50 of 62.9 μM), Bacillus anthracis (LT), Clostridium difficile toxin B (TcdB; EC50 of 73.3 µM), Clostridium sordellii lethal toxin (TcsL; EC50 of 86.7 μM)), three viruses (Ebola (EC50 of 3.3 µM), rabies (EC50 of 19.4 µM), dengue-4 virus ( EC50 of 8.2 µM)), two species of Chlamydiales intracellular bacteria (Simkania negevensis and Chlamydia trachomatis), and the parasite Leishmania infantum (EC50 of 7.1 µM) at micromolar level. In A549 cells, ABMA treatment induces a decrease in ricin cytotoxicity with an EC50 of 3.8 µM, and a protection factor (R) at 30 µM ranging from 5 to 10. ABMA retained almost 100% of its biological activity against ricin-induced cytotoxicity up to six days.
In Vivo:
ABMA (2-200 mg/kg; intraperitoneal injection; female BALB/c mice) treatment protects mice from nasal instillation of an LD90 of ricin.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.